Leerink Partners Initiates Coverage on Climb Bio (NASDAQ:CLYM)

Equities research analysts at Leerink Partners began coverage on shares of Climb Bio (NASDAQ:CLYM) in a research report issued on Monday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $10.00 price target on the stock. Leerink Partners’ price target would suggest a potential upside of 217.46% from the company’s current price.

Climb Bio Stock Down 3.4 %

Shares of Climb Bio stock opened at $3.15 on Monday. Climb Bio has a one year low of $2.35 and a one year high of $11.55.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.